AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

RVTY · NYSE · Medical - Diagnostics & Research

Revvity (RVTY)

Supplies research tools, scientific software, and clinical diagnostics from discovery through screening.

$141.17

vs last close−2.15 (−1.50%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Apr 2026	Q2 FY26Jul 2026
Revenue	671	696	650	692	684	729	665	720	699	772	711	730
Cost of revenue	298	402	295	306	299	370	289	328	324	434	323	313
Gross profit	373	294	355	386	385	360	376	393	375	338	388	417
	279	195	281	284	282	227	303	302	293	226	312	328
Research & development	53	50	50	48	49	49	54	53	51	58	58	49
	226	145	231	236	233	178	250	250	242	168	254	279
General & administrative	0	0	0	0	0	0	250	250	0	0	0	0
Other expenses	0	0	0	0	0	0	0	−2	0	0	0	0
Operating income	93	99	74	102	103	132	72	91	82	112	76	89
	−43	−68	−40	−15	−2	−38	−20	−22	−26	−20	−26	−26
Interest income	23	18	20	21	23	10	10	8	7	6	6	5
Interest expense	25	25	24	25	24	23	23	23	23	24	25	23
Other non-operating income	17	43	15	−10	−22	15	−3	−1	3	−3	1	3
Income before tax	51	31	35	87	100	95	52	69	56	92	50	64
Income tax expense	18	−32	6	14	7	6	11	13	8	−7	9	10
Net income from continuing operations	32	64	29	73	93	88	42	55	47	98	41	53
Discontinued operations	−23	39	−1	7	1	7	1	0	−1	0	0	−2
Net income	10	103	28	79	94	95	42	55	47	98	41	52
EPS, basic	$0.08	$0.83	$0.22	$0.64	$0.77	$0.78	$0.34	$0.47	$0.40	$0.87	$0.36	$0.47
EPS, diluted	$0.08	$0.83	$0.22	$0.64	$0.76	$0.78	$0.34	$0.47	$0.40	$0.87	$0.36	$0.47
Weighted average shares, basic	124	123	123	123	123	122	120	118	118	113	112	112
Weighted average shares, diluted	124	123	124	123	123	122	120	118	118	113	112	112
EBITDA	184	162	167	219	232	222	173	194	181	218	180	189
Depreciation & amortization	108	106	108	107	108	105	97	103	102	103	105	102
EBIT	76	56	59	111	125	117	75	92	78	115	75	87